CALTABIANO STEPHEN,OHLSTEIN ELIOT,MCCALLUM STEWART
申请号：
NZ60748511
公开号：
NZ607485A
申请日:
2011.08.02
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
The disclosure relates to pharmaceutical combinations comprising (i) a therapeutically effective amount of a beta-3 adrenergic receptor agonist selected from the group consisting of solabegron and pharmaceutically acceptable salts thereof, pharmaceutically acceptable solvates thereof and pharmaceutically acceptable salts thereof solvated with pharmaceutically acceptable solvents thereof； and (ii) a therapeutically effective amount, or a sub-therapeutically effective amount of a muscarinic receptor antagonist selected from the group consisting of tolterodine, oxybutynin, trospium, solifenacin, darifenacin, propiverine, fesoterodine, pharmaceutically acceptable salts thereof, a pharmaceutically acceptable solvates thereof, and pharmaceutically acceptable salt solvated with pharmaceutically acceptable solvent thereof, said combination being useful for relieving one or more symptoms associated with overactive bladder (OAB) in a synergistic manner, versus the individual components (i) and (ii). Preferred combinations include solabegron and oxybutynin. These pharmaceutical combinations are suitable for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence.
